Article Text

PDF
Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?
  1. F Cuculi,
  2. C C S Lim,
  3. A P Banning
  1. Department of Cardiology, Oxford Radcliffe Hospitals, Oxford, UK
  1. Correspondence to Dr Adrian P Banning, The John Radcliffe, Headley Way, Oxford OX3 9DU, UK; adrian.banning{at}orh.nhs.uk

Abstract

Periprocedural myocardial injury (PMI) is common after percutaneous coronary intervention (PCI). Periprocedural infarction (myocardial infarction type 4a) occurs after at least 10% of PCI procedures and has an impact on long-term prognosis. Measurement of biomarkers to allow assessment of PMI is an important tool for clinical and research purposes and should be routine after every PCI (troponin I or T and CK-MB). The importance of oral and intravenous antiplatelet agents and other drugs which have been proven to reduce PMI is discussed.

  • PTCA–troponin–statins
  • HMG CoA–clopidogrel–platelet aggregation inhibitors
  • coronary angioplasty
  • coronary stenting
  • microvascular
  • preconditioning
  • anticoagulation

Statistics from Altmetric.com

Footnotes

  • Funding APB is partially funded by the NIHR Biomedical Research Centre Oxford.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.